Charles River Laboratories International, Inc. logo
Charles River Laboratories International, Inc. (CRL)
Compare

Charles River Laboratories International, Inc. (CRL) Price/FCF Ratio: 23.52

Is Charles River Laboratories International, Inc.’s Price/FCF ratio high or low?

Charles River Laboratories International, Inc.'s Price/FCF ratio of 23.52 is 17% below its 5-year average of 28.35, around the middle of its 5-year range (10.17–48.61).

The Price/FCF ratio for Charles River Laboratories International, Inc. (CRL) is 23.52. It is above its 12-month average by 45.19% (16.20).

CRL Price/FCF Ratio Chart

CRL Price/FCF Ratio
23.52+72.56% 1Y
Zoom

CRL Average Price/FCF Ratio Chart

CRL Current vs Average Price/FCF Ratio Chart

CRL Price/FCF Ratio Metrics

PRICE/FCF RATIO

23.52

PRICE/FCF RATIO AVG TTM

16.20

PRICE/FCF RATIO AVG 3Y

22.79

PRICE/FCF RATIO AVG 5Y

28.35

PRICE/FCF RATIO AVG 10Y

25.63

PRICE/FCF RATIO AVG 15Y

21.99

PRICE/FCF RATIO AVG 20Y

36.82

CURRENT VS TTM AVG

+45.19%

CURRENT VS 3Y AVG

+3.20%

CURRENT VS 5Y AVG

-17.03%

CURRENT VS 10Y AVG

-8.24%

CURRENT VS 15Y AVG

+6.96%

CURRENT VS 20Y AVG

-36.12%

CRL Competitors' Price/FCF Ratio

NAMEMARKET CAPPRICE/FCF RATIOTTM3Y5Y
Charles River Laboratories International, Inc. (CRL)$9.06B23.5216.2022.7928.35
Bio-Rad Laboratories, Inc. (BIO)$7.89B22.0422.3039.2947.57
Baxter International Inc. (BAX)$10.49B14.6540.1431.0430.32
Hims & Hers Health, Inc. (HIMS)$6.42B86.6977.4670.8870.88
Align Technology, Inc. (ALGN)$12.56B18.3419.1231.1340.59
Hologic, Inc. (HOLX)$16.97B17.1816.1118.1314.57
Moderna, Inc. (MRNA)$18.40BN/A28.0727.2327.23
BioNTech SE (BNTX)$21.81B14.5836.2810.8414.33
Mettler-Toledo International Inc. (MTD)$22.85B28.9231.2531.1136.01
Waters Corporation (WAT)$23.83B113.8340.1239.3938.40

Free Cash Flow Valuation

P/FCF Ratio

23.5

FCF Yield

4.25%

Charles River Laboratories International, Inc. Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Charles River Laboratories International, Inc. Price/FCF Ratio FAQ

What is the Price/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
The Price/FCF ratio for CRL stock is 23.52.
Is Charles River Laboratories International, Inc.'s Price/FCF ratio high or low?
Charles River Laboratories International, Inc.'s Price/FCF ratio of 23.52 is 17% below its 5-year average of 28.35, around the middle of its 5-year range (10.17–48.61).
What is the TTM average Price/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
The TTM average Price/FCF ratio for CRL stock is 16.20.
What is the 3Y average Price/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
The 3Y average Price/FCF ratio for CRL stock is 22.79.
What is the 5Y average Price/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
The 5Y average Price/FCF ratio for CRL stock is 28.35.
What is the 10Y average Price/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
The 10Y average Price/FCF ratio for CRL stock is 25.63.
What is the 15Y average Price/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
The 15Y average Price/FCF ratio for CRL stock is 21.99.
What is the 20Y average Price/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
The 20Y average Price/FCF ratio for CRL stock is 36.82.

Charles River Laboratories International, Inc. Price/FCF Ratio History

DATEPRICE/FCF RATIO
2026-06-1023.52
2026-06-0923.75
2026-06-0823.32
2026-06-0522.69
2026-06-0423.24
2026-06-0322.50
2026-06-0221.87
2026-06-0122.78
2026-05-2922.61
2026-05-2822.69
2026-05-2720.58
2026-05-2619.61
2026-05-2220.05
2026-05-2119.87
2026-05-2019.52
2026-05-1919.07
2026-05-1818.76
2026-05-1518.87
2026-05-1419.91
2026-05-1320.37
2026-05-1221.10
2026-05-1121.07
2026-05-0822.22
2026-05-0722.73
2026-05-0617.25
2026-05-0517.60
2026-05-0416.36
2026-05-0115.74
2026-04-3015.85
2026-04-2915.55
2026-04-2815.83
2026-04-2716.25
2026-04-2416.12
2026-04-2315.92
2026-04-2217.54
2026-04-2117.38
2026-04-2017.61
2026-04-1717.45
2026-04-1616.80
2026-04-1517.14
2026-04-1417.02
2026-04-1316.93
2026-04-1016.67
2026-04-0916.66
2026-04-0816.62
2026-04-0716.09
2026-04-0615.97
2026-04-0216.51
2026-04-0116.60
2026-03-3116.37
2026-03-3015.16
2026-03-2715.11
2026-03-2615.67
2026-03-2515.75
2026-03-2415.11
2026-03-2315.00
2026-03-2014.58
2026-03-1914.53
2026-03-1814.91
2026-03-1714.59
2026-03-1614.43
2026-03-1314.76
2026-03-1214.49
2026-03-1116.03
2026-03-1015.89
2026-03-0916.80
2026-03-0616.56
2026-03-0517.21
2026-03-0417.05
2026-03-0316.68
2026-03-0216.95
2026-02-2716.94
2026-02-2616.65
2026-02-2515.90
2026-02-2415.76
2026-02-2315.52
2026-02-2016.03
2026-02-1915.59
2026-02-1815.00
2026-02-1714.41
2026-02-1314.67
2026-02-1214.43
2026-02-1115.09
2026-02-1016.48
2026-02-0916.88
2026-02-0617.20
2026-02-0516.70
2026-02-0418.33
2026-02-0318.31
2026-02-0219.38
2026-01-3019.14
2026-01-2919.24
2026-01-2819.72
2026-01-2719.96
2026-01-2620.21
2026-01-2319.97
2026-01-2220.37
2026-01-2120.62
2026-01-2019.84
2026-01-1619.97
2026-01-1520.32
2026-01-1419.67
2026-01-1319.91
2026-01-1219.89
2026-01-0920.08
2026-01-0819.59
2026-01-0719.71
2026-01-0619.65
2026-01-0518.94
2026-01-0218.40
2025-12-3118.14
2025-12-3018.36
2025-12-2918.47
2025-12-2618.52
2025-12-2418.47
2025-12-2318.44
2025-12-2218.46
2025-12-1917.92
2025-12-1817.62
2025-12-1717.82
2025-12-1617.75
2025-12-1518.01
2025-12-1217.55
2025-12-1117.68
2025-12-1017.71
2025-12-0916.91
2025-12-0817.01
2025-12-0516.76
2025-12-0416.73
2025-12-0316.79
2025-12-0215.89
2025-12-0116.01
2025-11-2816.20
2025-11-2616.27
2025-11-2516.19
2025-11-2415.50
2025-11-2115.24
2025-11-2014.73
2025-11-1914.69
2025-11-1814.78
2025-11-1714.79
2025-11-1415.26
2025-11-1315.38
2025-11-1215.59
2025-11-1115.77
2025-11-1015.36
2025-11-0715.28
2025-11-0615.54
2025-11-0515.25
2025-11-0415.16
2025-11-0315.25
2025-10-3115.35
2025-10-3015.27
2025-10-2915.36
2025-10-2816.02
2025-10-2716.65
2025-10-2416.80
2025-10-2316.28
2025-10-2215.94
2025-10-2116.05
2025-10-2015.70
2025-10-1715.22
2025-10-1614.91
2025-10-1514.55
2025-10-1414.50
2025-10-1314.55
2025-10-1014.24
2025-10-0914.67
2025-10-0814.79
2025-10-0714.50
2025-10-0614.91
2025-10-0315.12
2025-10-0214.95
2025-10-0114.53
2025-09-3013.34
2025-09-2912.53
2025-09-2612.66
2025-09-2512.41
2025-09-2412.74
2025-09-2312.81
2025-09-2213.12
2025-09-1913.25
2025-09-1813.38
2025-09-1713.02
2025-09-1612.92
2025-09-1512.98
2025-09-1213.03
2025-09-1113.62
2025-09-1013.07
2025-09-0913.42
2025-09-0813.81
2025-09-0513.98
2025-09-0413.84
2025-09-0313.84
2025-09-0213.75
2025-08-2913.92
2025-08-2813.91
2025-08-2713.88
2025-08-2613.96
2025-08-2513.99
2025-08-2213.80
2025-08-2113.17
2025-08-2013.60
2025-08-1913.51
2025-08-1813.38
2025-08-1513.36
2025-08-1413.28
2025-08-1313.21
2025-08-1213.02
2025-08-1112.70
2025-08-0812.68
2025-08-0712.77
2025-08-0612.82
2025-08-0515.12
2025-08-0415.16
2025-08-0115.07
2025-07-3115.32
2025-07-3015.91
2025-07-2916.11
2025-07-2816.16
2025-07-2515.97
2025-07-2415.99
2025-07-2315.16
2025-07-2214.75
2025-07-2113.52
2025-07-1813.95
2025-07-1714.15
2025-07-1613.99
2025-07-1513.94
2025-07-1414.27
2025-07-1114.39
2025-07-1014.78
2025-07-0914.35
2025-07-0814.30
2025-07-0713.90
2025-07-0314.19
2025-07-0214.22
2025-07-0113.94
2025-06-3013.70
2025-06-2713.54
2025-06-2613.69
2025-06-2513.56
2025-06-2413.40
2025-06-2313.31
2025-06-2013.31
2025-06-1813.12
2025-06-1713.10
2025-06-1613.64
2025-06-1313.49
2025-06-1213.71
2025-06-1113.64
2025-06-1013.63
2025-06-0913.31
2025-06-0613.06
2025-06-0512.75
2025-06-0412.93
2025-06-0312.50
2025-06-0212.19
2025-05-3012.25
2025-05-2912.43

Showing the most recent 260 of 4,916 data points. The chart above shows the full history.

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wilmington, MA
18,700 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
James C. Foster